100 Recruiting Studies Using Fulvestrant
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Fulvestrant
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
π UCLA Jonsson Comp Cancer Center β Los Angeles, California
Breast Cancer
View Study & Checklist βNab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
π OU Health Stephenson Cancer Center β Oklahoma City, Oklahoma
Low Grade Ovarian Serous Adenocarcinoma
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
π Alaska Oncology & Hematology, LLC β Anchorage, Alaska
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
View Study & Checklist βCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
π Research Site β Tucson, Arizona
Locally Advanced (Inoperable) or Metastatic Breast Cancer
View Study & Checklist βFulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
π Southern Highlands Cancer Centre β Bowral, New South Wales
Breast Cancer
View Study & Checklist βFirst-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
π California Cancer Associates for Research and Excellence β Encinitas, California
Advanced Cancer
View Study & Checklist βStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
π Novartis Investigative Site β Sint-Niklaas, Oost Vlaanderen
Breast Cancer
View Study & Checklist βTo Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
π Massachusetts General Hospital. β Boston, Massachusetts
Breast Cancer
View Study & Checklist βAbemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
π St. Joseph's Hospital and Medical Center β Phoenix, Arizona
Breast Neoplasm
View Study & Checklist βOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
π Clinical Trial Site β Tucson, Arizona
Breast Cancer
View Study & Checklist βStudy of INCB123667 in Subjects With Advanced Solid Tumors
π City of Hope Medical Center β Duarte, California
Solid Tumors
View Study & Checklist βRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
π UCLA / Jonsson Comprehensive Cancer Center β Los Angeles, California
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist βGedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
π University of Alabama at Birmingham β Birmingham, Alabama
Breast Cancer
View Study & Checklist βA Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
π Research Site β Commack, New York
Metastatic Breast Cancer
View Study & Checklist βPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
π Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital β Washington D.C., District of Columbia
Metastatic Breast Cancer
View Study & Checklist βDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
π University of Arizona Cancer Center β Tucson, Arizona
Breast Cancer
View Study & Checklist βStudy of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
π Michigan State University, Breslin Cancer Center β Lansing, Michigan
Breast Cancer
View Study & Checklist βPembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
π City of Hope Corona β Corona, California
Metastatic Breast Carcinoma
View Study & Checklist βA Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
π Research Site β Birmingham, Alabama
Advanced ER-Positive HER2-Negative Breast Cancer
View Study & Checklist βFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Estrogen Receptor-positive Breast Cancer
View Study & Checklist βRoll-over Study to Allow Continued Access to Ribociclib
π Ironwood Cancer and Research Centers β Chandler, Arizona
Metastatic Breast Cancer
View Study & Checklist βPreventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
π Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) β Basking Ridge, New Jersey
Breast Cancer
View Study & Checklist βPalbociclib After CDK and Endocrine Therapy (PACE)
π University of Miami β Miami, Florida
Metastatic Breast Cancer
View Study & Checklist βA Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
π Highlands Oncology Group - Duplicate 2 β Rogers, Arkansas
Breast Neoplasms
View Study & Checklist βComparison of Fulvestrant (FASLODEXβ’) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
π Research Site β Casa Grande, Arizona
Breast Cancer
View Study & Checklist βCapivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
π Research Site β Gilbert, Arizona
Locally Advanced (Inoperable) or Metastatic Breast Cancer
View Study & Checklist βRandomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
π UCSF β San Francisco, California
HER-2 Positive Breast Cancer
View Study & Checklist βCFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
π The Ohio State University Comprehensive Cancer Center β Columbus, Ohio
Advanced Solid Tumor
View Study & Checklist βClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
π University of Colorado Cancer Center β Aurora, Colorado
HER2-positive Metastatic Breast Cancer
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
π Northwest Georgia Oncology Centers PC - Marietta β Marietta, Georgia
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
View Study & Checklist βPreoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
π University of Colorado β Aurora, Colorado
Breast Cancer
View Study & Checklist βStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
π City of Hope - Phoenix ( Site 0006) β Goodyear, Arizona
Metastatic Breast Cancer
View Study & Checklist βA Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
π Hoag Memorial Presbyterian β Newport Beach, California
Breast Cancer
View Study & Checklist βStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
π Ellison Institute β Los Angeles, California
Liposarcoma
View Study & Checklist βFulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
π University of Texas MD Anderson Cancer Center β Houston, Texas
Malignant Neoplasms of Female Genital Organs
View Study & Checklist βAKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
π Massachusetts General Hospital Cancer Center β Boston, Massachusetts
Breast Cancer
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
π Cancer Blood and Specialty Clinic β Los Alamitos, California
Breast Cancer
View Study & Checklist βA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
π St. Bernards Medical Center β Jonesboro, Arkansas
Breast Neoplasms
View Study & Checklist βA Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
π Hoag Health Center Irvine β Irvine, California
Advanced or Metastatic Breast Cancer
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
π Beverly Hills Cancer Center β Beverly Hills, California
Breast Cancer
View Study & Checklist βAlpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
π University of Illinois Cancer Center β Chicago, Illinois
Hormone Receptor Positive Breast Carcinoma
View Study & Checklist βA Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
π City of Hope β Duarte, California
Endometroid Endometrial Cancer
View Study & Checklist βTesting the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist βA Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
π California Cancer Associates for Research and Excellence, Inc. (cCARE) β Encinitas, California
Advanced Breast Cancer
View Study & Checklist βPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
π Banner MD Anderson Cancer Center β Gilbert, Arizona
Metastatic Breast Cancer
View Study & Checklist βA Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
π Ironwood Cancer & Research Centers β Chandler, Arizona
Breast Neoplasms
View Study & Checklist βBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
π HonorHealth β Phoenix, Arizona
Uterine Neoplasms
View Study & Checklist βStudy for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
π UCSF Medical Center at Mission Bay β San Francisco, California
Breast Cancer
View Study & Checklist βEfficacy and Safety of 500mg of Fulvestrant
π Massachusetts General Hosptial β Boston, Massachusetts
Breast Cancer
View Study & Checklist βFunctional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
π Siteman Cancer Center at Washington University β St Louis, Missouri
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist βOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
π Florida Cancer Specialists β Orlando, Florida
Breast Cancer
View Study & Checklist βStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
π HonorHealth β Scottsdale, Arizona
Locally Advanced or Metastatic ER+ HER2- Breast Cancer
View Study & Checklist βSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
π Moffitt Cancer Center β Tampa, Florida
Metastatic Breast Cancer
View Study & Checklist βA Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
π Mayo Clinic of Scottsdale β Scottsdale, Arizona
Breast Cancer
View Study & Checklist βPhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
π Banner MD Anderson Cancer Center β Gilbert, Arizona
PIK3CA Mutation
View Study & Checklist βA Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
π City of Hope β Duarte, California
HR+ Breast Cancer
View Study & Checklist βTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist βA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
π Los Angeles Cancer Network - Anaheim β Anaheim, California
Breast Cancer
View Study & Checklist βRash & Diarrhea Prophylaxis With Capivasertib
π Yale University β New Haven, Connecticut
Metastatic HR+/HER2- Breast Cancer
View Study & Checklist βLiquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
π Arthur J.E. Child Comprehensive Cancer Centre β Calgary, Alberta
Breast Cancer
View Study & Checklist βMultiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
π Floridian Clinical Research LLC β Miami Lakes, Florida
Healthy Postmenopausal Women
View Study & Checklist βA Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
π Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) β Basking Ridge, New Jersey
Metastatic Breast Cancer
View Study & Checklist βFirst-in-Human Study of Mutant-selective PI3KΞ± Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
π The University of Arizona Cancer Center β Tucson, Arizona
PIK3CA Mutation
View Study & Checklist βStudy of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
π Yale New Haven Hospital β New Haven, Connecticut
Advanced HR+/HER2- Breast Cancer
View Study & Checklist βVS-6766+Abema+Fulv in Met HR+/HER- BC
π Massachusetts General Hospital Cancer Center β Boston, Massachusetts
Breast Cancer
View Study & Checklist βEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
π Mayo Clinic - Scottsdale β Scottsdale, Arizona
Metastatic Breast Cancer
View Study & Checklist βBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
π University of Iowa Hospitals and Clinics β Iowa City, Iowa
Hormone-receptor-positive Breast Cancer
View Study & Checklist βFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
π Ellison Clinic at Saint John's β Los Angeles, California
Breast Cancer
View Study & Checklist βSafety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
π Biotheryx Investigative Site β Rochester, Minnesota
Breast Cancer
View Study & Checklist βPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
π Yale School of Medicine β New Haven, Connecticut
Hormone Receptor-positive Breast Cancer
View Study & Checklist βStudy of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
π University of Arizona β Tucson, Arizona
Melanoma (Skin Cancer)
View Study & Checklist βStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
π Emory University β Atlanta, Georgia
Advanced HR+/HER2- Breast Cancer
View Study & Checklist βEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
π Washington University School of Medicine β St Louis, Missouri
Breast Cancer
View Study & Checklist βA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
π Alaska Oncology and Hematology β Anchorage, Alaska
Breast Neoplasms
View Study & Checklist βFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
π Houston Methodist Cancer Center β Houston, Texas
ER-Positive Breast Cancer
View Study & Checklist βORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
π Avenzo Therapeutics Recruiting Site β Los Angeles, California
HR+/HER2- Breast Cancer
View Study & Checklist βSapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
π START Los Angeles β Los Angeles, California
HR+ HER2- Breast Cancer
View Study & Checklist βBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
π Sarah Cannon Research Institute (Scri) At Health One β Denver, Colorado
Advanced Solid Tumor
View Study & Checklist βAnastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
π Chao Family Comprehensive Cancer Center, University of California, Irvine β Orange, California
Breast Cancer
View Study & Checklist βPhase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
π Florida Cancer Specialists β Sarasota, Florida
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
View Study & Checklist βA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
π University of Alabama at Birmingham β Birmingham, Alabama
Advanced Solid Tumor
View Study & Checklist βA Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
π University of Alabama At Birmingham Hospital β Birmingham, Alabama
Advanced Solid Tumor
View Study & Checklist βA Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
π City of Hope (City of Hope National Medical Center, City of Hope Medical Center) β Duarte, California
Advanced Breast Cancer
View Study & Checklist βRibociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
π University of Alabama at Birmingham β Birmingham, Alabama
Locoregional Recurrence
View Study & Checklist βStudy of AVZO-021 in Patients With Advanced Solid Tumors
π Yale Cancer Center β New Haven, Connecticut
Advanced Solid Tumor
View Study & Checklist βTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
π Los Angeles Cancer Network β Los Angeles, California
Breast Cancer
View Study & Checklist βA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
π City of Hope β Duarte, California
Breast Cancer
View Study & Checklist βRegorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
π University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center β Cleveland, Ohio
Ovarian Cancer
View Study & Checklist βA Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
π Northwestern Memorial Hospital β Chicago, Illinois
HR+/HER2-negative Breast Cancer
View Study & Checklist βReversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
π Northwestern Memorial Hospital β Chicago, Illinois
Inguinal Hernia Unilateral
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
π City of Hope β Duarte, California
Metastatic Breast Cancer
View Study & Checklist βStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
π University of California LA β Los Angeles, California
Advanced HR+/HER2- Breast Cancer
View Study & Checklist βA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
π Southern Cancer Center β Daphne, Alabama
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
View Study & Checklist βSNV4818 in Participants With Advanced Solid Tumors
π The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate β Los Angeles, California
Advanced Solid Tumors
View Study & Checklist βA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
π Ironwood Cancer & Research Centers β Chandler, Arizona
Breast Cancer
View Study & Checklist βA Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
π Alaska Womens Cancer Care ( Site 0037) β Anchorage, Alaska
Malignant Neoplasm
View Study & Checklist βA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
π Florida Clinical Trials Group β Plantation, Florida
ER+, HER 2- Breast Cancer
View Study & Checklist βGenetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
π Dartmouth Hitchcock Medical Center β Lebanon, New Hampshire
Advanced Breast Cancer
View Study & Checklist βOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
π City of Hope Comprehensive Cancer Center β Duarte, California
Solid Tumor, Adult
View Study & Checklist βStudy to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
π University of Chicago Medicine Comprehensive Cancer Center β Chicago, Illinois
Metastatic Pancreatic Neuroendocrine Tumor
View Study & Checklist β